Material and Methods
This prospective study was conducted between January and November 2018
in the Obstetrics & Gynecology and Biochemistry Departments of the
Harran University Medical Faculty in Sanliurfa, Turkey.
This study conformed with the
principles of the 2008 Declaration of Helsinki and was approved by the
local ethics committee of the Harran University Medical Faculty.
Detailed information was provided to all of the women enrolled in this
study, and written consent was given by all of the patients.
The study included 23 pregnant women with HM at 7 to 12 weeks of
gestation and 24 age and gestational week matched healthy pregnant
women. Any individuals with diabetes, thyroid dysfunction or
hypertension, multiple gestations, and women whose pathology results
were other types of gestational trophoblastic disease, and women who use
vitamins or smoke were excluded from the study. The HM diagnosis was
made via USG results (Voluson 730 Expert scanner; GE Healthcare,
Milwaukee, WI, USA) showing typical complete mole appearance (snowstorm
appearance). In addition, patients’ ovaries were evaluated in terms of
theca lutein cyst during ultrasonographic examination. In all cases, the
preoperative diagnosis of HM was confirmed by postoperative
histopathology results.
Each woman’s age, body mass index (BMI), gravidity, parity, blood
pressure, thyroid function test, β-hcg level, and urine analysis were
documented. The venous blood
samples were collected preoperatively when the HM diagnosis was made for
the biochemical comparisons between the groups.